Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-02

Shattuck Labs (STTK)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,532,763
Taylor Schreiber total, FY2025
1st
CEO pay percentile vs peers
CEO-to-median pay ratio
91.96%
Say-on-pay support, latest vote
Companies that benchmark against STTK
No companies currently name STTK as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Taylor Schreiber$565,600$0$0$656,531$296,940$0$13,692$1,532,763
Chief Executive Officer
Arunthathy Nirmalini (Lini) Pandite502,98000197,746211,252020,667932,645
Chief Medical Officer
Andrew Neill467,16000205,226196,207014,840883,433
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Taylor Schreiber$1,532,763
Arunthathy Nirmalini (Lini) Pandite932,645
Andrew Neill883,433

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Arunthathy Nirmalini (Lini) PanditeRSU18,937$69,120
Andrew NeillRSU42,375154,669
Arunthathy Nirmalini (Lini) PanditeRSU34,856127,224
Andrew NeillRSU17,46263,736
Arunthathy Nirmalini (Lini) PanditeRSU8,68431,697
Andrew NeillRSU8,33130,408
Taylor SchreiberOption171,9289.41
Taylor SchreiberOption684,6001.18
Arunthathy Nirmalini (Lini) PanditeOption1,4477.43
Arunthathy Nirmalini (Lini) PanditeOption18,8923.57
Arunthathy Nirmalini (Lini) PanditeOption48,41210.09
Arunthathy Nirmalini (Lini) PanditeOption206,2001.18
Andrew NeillOption1,3897.43
Andrew NeillOption214,0001.18
Andrew NeillOption18,9183.57
Andrew NeillOption58,85510.09
05

Incentive-plan design — the Compensation Discussion & Analysis

The objectives of the Compensation Committee’s compensation philosophy are to attract, retain, and motivate superior executive talent through providing incentives that reward the achievement of performance goals correlated to enhancing shareholder value and aligning the executive’s interests with those of shareholders through long-term incentives linked to specific performance.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantAon
Clawback policy
Anti-hedging
Anti-pledging
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2849,849,8874,356,1991,66091.96%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2891.96%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)7,500 / 10,000 / 10,000
Stock ownership guideline
10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

PMVP PMV PharmaceuticalsCTMX CytomX TherapeuticsBTAI BioAtlaALXN ALX OncologyITOS Iteos TherapeuticsGRST Gritstone bioIGMB IGM BiosciencesHOOK HOOKIPA PharmaKEZR Kezar Life SciencesBDTX Black Diamond TherapeuticsPSBN Precision BioSciencesMRSN Mersana TherapeuticsPRDL Prelude TherapeuticsPCG PrecigenCTRX Century TherapeuticsORIC ORIC Pharmaceuticals
10a

Peer reciprocity

Of the companies Shattuck Labs names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

PMV Pharmaceuticals (PMVP) CytomX Therapeutics (CTMX) BioAtla (BTAI) ALX Oncology (ALXN) Iteos Therapeutics (ITOS) Gritstone bio (GRST) IGM Biosciences (IGMB) HOOKIPA Pharma (HOOK) Kezar Life Sciences (KEZR) Black Diamond Therapeutics (BDTX) Precision BioSciences (PSBN) Mersana Therapeutics (MRSN)11 Prelude Therapeutics (PRDL) Precigen (PCG)12 Century Therapeutics (CTRX) ORIC Pharmaceuticals (ORIC)

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Shattuck Labs.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Precigen2025Patricia Poppe$1,400,000$11,155,472$0$2,919,000$19,812,481
2Iteos Therapeutics2024Michel Detheux628,68404,965,264421,0146,085,657
3ORIC Pharmaceuticals2025Jacob Chacko657,500826,0003,634,560434,0005,567,164
4Black Diamond Therapeutics2025Mark Velleca667,400189,0001,006,030348,7172,234,919
5Mersana Therapeutics2024Michael Huber632,500133,635518,044322,5751,613,754
6Shattuck Labs2025Taylor Schreiber565,6000656,531296,9401,532,763
PMV Pharmaceuticalsnot in coverage universe
CytomX Therapeuticsnot in coverage universe
BioAtlanot in coverage universe
ALX Oncologynot in coverage universe
Gritstone bionot in coverage universe
IGM Biosciencesnot in coverage universe
HOOKIPA Pharmanot in coverage universe
Kezar Life Sciencesnot in coverage universe
Precision BioSciencesnot in coverage universe
Prelude Therapeuticsnot in coverage universe
Century Therapeuticsnot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Shattuck Labsnot disclosedOption 100not disclosedAon
ALX Oncologynot disclosednot disclosednot disclosednot disclosed
BioAtlanot disclosednot disclosednot disclosednot disclosed
Black Diamond Therapeutics95%not disclosednot disclosedAon Human Capital Solutions (Aon plc)
Century Therapeuticsnot disclosednot disclosednot disclosednot disclosed
CytomX Therapeuticsnot disclosednot disclosednot disclosednot disclosed
Gritstone bionot disclosednot disclosednot disclosednot disclosed
HOOKIPA Pharmanot disclosednot disclosednot disclosednot disclosed
IGM Biosciencesnot disclosednot disclosednot disclosednot disclosed
Iteos Therapeuticsnot disclosednot disclosednot disclosedRadford
Kezar Life Sciencesnot disclosednot disclosednot disclosednot disclosed
Mersana Therapeutics85%Options 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
ORIC Pharmaceuticalsnot disclosednot disclosednot disclosedAon
PMV Pharmaceuticalsnot disclosednot disclosednot disclosednot disclosed
Precigennot disclosednot disclosedYes — Relative TSRMeridian Compensation Partners, LLC
Precision BioSciencesnot disclosednot disclosednot disclosednot disclosed
Prelude Therapeuticsnot disclosednot disclosednot disclosednot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Taylor SchreiberDEF 14A2026-04-080001193125-26-146293Section “Executive Compensation”. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812
2Section 01, Arunthathy Nirmalini (Lini) PanditeDEF 14A2026-04-080001193125-26-146293Section “Executive Compensation”. As printed: 932,645. Filing ↗machine: r4 · c27 · span 279148–279155
3Section 01, Andrew NeillDEF 14A2026-04-080001193125-26-146293Section “Executive Compensation”. As printed: 883,433. Filing ↗machine: r6 · c27 · span 283449–283456
4Section 06, 2026 voteForm 8-K2026-06-020001193125-26-253784Item 5.07 · say-on-pay result. As reported: 91.96% (votes for as printed: 49,849,887). Filing ↗
5Precigen, Section 10b CEO totalDEF 14A2026-04-090001004980-26-000020CEO total compensation as printed in Precigen's own proxy. As printed: 19,812,481. Filing ↗machine: t111 · r2 · c16 · span 1281710–1281720
6Iteos Therapeutics, Section 10b CEO totalDEF 14A2025-04-240000950170-25-057666CEO total compensation as printed in Iteos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281
7ORIC Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-280001193125-26-186911CEO total compensation as printed in ORIC Pharmaceuticals's own proxy. As printed: 5,567,164. Filing ↗machine: r2 · c26 · span 435191–435200
8Black Diamond Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001104659-26-051474CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. Filing ↗machine: r1 · c41 · span 370031–370040
9Mersana Therapeutics, Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197
10Shattuck Labs (subject), Section 10b CEO totalDEF 14A2026-04-080001193125-26-146293CEO total compensation as printed in Shattuck Labs's own proxy. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812
11Section 10a, Mersana Therapeutics reciprocityDEF 14A0001104659-25-040448Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗
12Section 10a, Precigen reciprocityDEF 14A0001004980-26-000020Precigen's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗